The aims of the GHSG’s current trials are to further optimize first-line treatment in all stages of Hodgkin lymphoma and to improve therapy for relapsed patients, while minimizing treatment-related adverse effects and maintaining treatment efficacy.
|HD17||Treatment optimization trial in the first-line treatment of intermediate stage Hodgkin lymphoma; treatment stratification by means of FDG-PET||Intermediate stages||Phase III, multicenter, randomized|
|B-CAP||Brentuximab vedotin or B-CAP in the treatment of older patients with newly diagnosed classical Hodgkin lymphoma – a GHSG-NLG Intergroup phase II trial||all stages||Phase II, multicenter|
Treatment of relapses
|HD-R3i||A phase II trial to evaluate the safety of RAD001 (everolimus) in combination with DHAP standard chemotherapy in patients with relapsed or refractory Hodgkin lymphoma||relapsed / refractory HL, all stages||Phase II, multicenter|
|GHSG-AFM13||An open-label, randomized, multicenter phase II trial with AFM13 in patients with relapsed or treatment-resistant Hodgkin Lymphoma||relapsed / refractory HL, all stages||Phase II, multicenter, randomized|
|JeRiCHO||JAK-inhibition in recurrent classical Hodgkin Lymphoma: Ruxolitinib in patients with recurrent classical Hodgkin lymphoma – a phase II trial||relapsed / refractory HL, all stages||Phase II, multicenter|